Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis
Venetoclax (VEN), in combination with low dose cytarabine (AraC) or a hypomethylating agent, is FDA approved to treat acute myeloid leukemia (AML) in patients who are over the age of 75 or cannot tolerate standard chemotherapy. Despite high response rates to these combination therapies, most patients succumb to the disease due to relapse and/or drug resistance, providing an unmet clinical need for novel therapies to improve AML patient survival. ME-344 is a potent isoflavone with demonstrated inhibitory activity toward oxidative phosphorylation (OXPHOS) and clinical activity in solid tumors. Given that OXPHOS inhibition enhances VEN antileukemic activity against AML, we hypothesized that ME-344 could enhance the anti-AML activity of VEN. Here we report that ME-344 synergized with VEN to target AML cell lines and primary patient samples while sparing normal hematopoietic cells. Cooperative suppression of OXPHOS was detected in a subset of AML cell lines and primary patient samples. Metabolomics analysis revealed a significant reduction of purine biosynthesis metabolites by ME-344. Further, lometrexol, an inhibitor of purine biosynthesis, synergistically enhanced VEN-induced apoptosis in AML cell lines. Interestingly, AML cells with acquired resistance to AraC showed significantly increased purine biosynthesis metabolites and sensitivities to ME-344. Furthermore, synergy between ME-344 and VEN was preserved in these AraC-resistant AML cells. These results translated into significantly prolonged survival upon combination of ME-344 and VEN in NSGS mice bearing parental or AraC-resistant MV4-11 leukemia. This study demonstrates that ME-344 enhances VEN antileukemic activity against preclinical models of AML by suppressing OXPHOS and/or purine biosynthesis.
| Errataetall: |
UpdateIn: Biochem Pharmacol. 2023 Dec 10;220:115981. - PMID 38081370 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Research square - (2023) vom: 28. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hurrish, Katie H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute myeloid leukemia |
|---|
| Anmerkungen: |
Date Revised 27.01.2024 published: Electronic UpdateIn: Biochem Pharmacol. 2023 Dec 10;220:115981. - PMID 38081370 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.21203/rs.3.rs-2843025/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356658740 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356658740 | ||
| 003 | DE-627 | ||
| 005 | 20240128231831.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-2843025/v1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1273.xml |
| 035 | |a (DE-627)NLM356658740 | ||
| 035 | |a (NLM)37162954 | ||
| 035 | |a (PII)rs.3.rs-2843025 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hurrish, Katie H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: Biochem Pharmacol. 2023 Dec 10;220:115981. - PMID 38081370 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Venetoclax (VEN), in combination with low dose cytarabine (AraC) or a hypomethylating agent, is FDA approved to treat acute myeloid leukemia (AML) in patients who are over the age of 75 or cannot tolerate standard chemotherapy. Despite high response rates to these combination therapies, most patients succumb to the disease due to relapse and/or drug resistance, providing an unmet clinical need for novel therapies to improve AML patient survival. ME-344 is a potent isoflavone with demonstrated inhibitory activity toward oxidative phosphorylation (OXPHOS) and clinical activity in solid tumors. Given that OXPHOS inhibition enhances VEN antileukemic activity against AML, we hypothesized that ME-344 could enhance the anti-AML activity of VEN. Here we report that ME-344 synergized with VEN to target AML cell lines and primary patient samples while sparing normal hematopoietic cells. Cooperative suppression of OXPHOS was detected in a subset of AML cell lines and primary patient samples. Metabolomics analysis revealed a significant reduction of purine biosynthesis metabolites by ME-344. Further, lometrexol, an inhibitor of purine biosynthesis, synergistically enhanced VEN-induced apoptosis in AML cell lines. Interestingly, AML cells with acquired resistance to AraC showed significantly increased purine biosynthesis metabolites and sensitivities to ME-344. Furthermore, synergy between ME-344 and VEN was preserved in these AraC-resistant AML cells. These results translated into significantly prolonged survival upon combination of ME-344 and VEN in NSGS mice bearing parental or AraC-resistant MV4-11 leukemia. This study demonstrates that ME-344 enhances VEN antileukemic activity against preclinical models of AML by suppressing OXPHOS and/or purine biosynthesis | ||
| 650 | 4 | |a Preprint | |
| 650 | 4 | |a Acute myeloid leukemia | |
| 650 | 4 | |a ME-344 | |
| 650 | 4 | |a oxidative phosphorylation | |
| 650 | 4 | |a purine biosynthesis | |
| 650 | 4 | |a venetoclax | |
| 700 | 1 | |a Su, Yongwei |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Shraddha |e verfasserin |4 aut | |
| 700 | 1 | |a Ramage, Cassandra L |e verfasserin |4 aut | |
| 700 | 1 | |a Carter, Jenna L |e verfasserin |4 aut | |
| 700 | 1 | |a Edwards, Holly |e verfasserin |4 aut | |
| 700 | 1 | |a Buck, Steven A |e verfasserin |4 aut | |
| 700 | 1 | |a Wiley, Sandra E |e verfasserin |4 aut | |
| 700 | 1 | |a Hüttemann, Maik |e verfasserin |4 aut | |
| 700 | 1 | |a Polin, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Kushner, Juiwanna |e verfasserin |4 aut | |
| 700 | 1 | |a Dzinic, Sijana H |e verfasserin |4 aut | |
| 700 | 1 | |a White, Kathryn |e verfasserin |4 aut | |
| 700 | 1 | |a Bao, Xun |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jay |e verfasserin |4 aut | |
| 700 | 1 | |a Boerner, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Hou, Zhanjun |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Atrash, Gheath |e verfasserin |4 aut | |
| 700 | 1 | |a Konoplev, Sergej N |e verfasserin |4 aut | |
| 700 | 1 | |a Busquets, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Tiziani, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Matherly, Larry H |e verfasserin |4 aut | |
| 700 | 1 | |a Taub, Jeffrey W |e verfasserin |4 aut | |
| 700 | 1 | |a Konopleva, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Ge, Yubin |e verfasserin |4 aut | |
| 700 | 1 | |a Baran, Natalia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Research square |d 2020 |g (2023) vom: 28. Apr. |w (DE-627)NLM312780982 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:28 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-2843025/v1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 28 |c 04 | ||